Filing Flows › X4 Pharmaceuticals (XFOR) › Q1 2025
X4 Pharmaceuticals (XFOR) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
X4 Pharmaceuticals (XFOR) reported revenue of $900K for the first quarter 2025 (Q1 2025) and -40% from the quarter before.
X4 Pharmaceuticals, Q1 2025: revenue $900K, net earnings $282K, operating cash flow −$12.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $900K | -40% | — |
| Operating profit | −$9.4M | — | — |
| Net earnings | $282K | — | — |
| Operating cash flow | −$12.4M | — | — |
What changed
Revenue was $900K in Q1 2025, down 40% from the previous quarter. License and other revenue was the largest line, $27.9M against total revenue of $900K (other lines net negative).
Operating costs exceeded revenue by $9.4M, an operating margin of -1049.2%. Net earnings were $282K. The effective tax rate was 10.8%. Non-operating items added $9.8M, 3088% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$12.4M. Non-cash charges added back $476K of depreciation and amortization and $519K of share-based compensation. Working capital and other items used $13.6M.
Questions
What was X4 Pharmaceuticals' revenue in the first quarter 2025?
X4 Pharmaceuticals (XFOR) reported revenue of $900K for the first quarter 2025 (Q1 2025) and -40% from the quarter before.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.